Topical endoxifen + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mammographic Breast Density
Conditions
Mammographic Breast Density
Trial Timeline
Apr 9, 2018 → Sep 4, 2019
NCT ID
NCT04616430About Topical endoxifen + Placebo
Topical endoxifen + Placebo is a phase 2 stage product being developed by Atossa Therapeutics for Mammographic Breast Density. The current trial status is completed. This product is registered under clinical trial identifier NCT04616430. Target conditions include Mammographic Breast Density.
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04616430 | Phase 2 | Completed |